Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
A controlled study with two arms was performed in 153 evaluable patients with advanced breast cancer. All patients were postmenopausal and untreated. The first combination included cyclophosphamide, methotrexate, 5-fluorouracil (CMF, 82 patients) while the second one contained the same cytostatic combination and tamoxifen (zitazonium) (CMF + T, 71 patients). Patients were prospectively stratified according to the dominant sites of metastases and randomized to the respective treatment schedule. In CMF combination the response rate (CR + PR) was 33/82 (40%) and complete response (CR) 8/82 (10%), respectively. In the CMF + T arm the corresponding values were 29/71 (41%) and 14/71 (20%), respectively. From the analysis of the data the superiority of the CMF + T arm could be established concerning CR in soft tissue and CR + PR in bone localization.